Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study

Angioedema and Fatty Acids

“…A recently updated understanding of angioedema helped to develop novel therapeutic options, especially lanadelumab and berotralstat, which target the upstream factors, accelerating bradykinin production. Lanadelumab is a human-specific monoclonal antibody targeting plasma kallikrein that acts as an inhibitor and reduces downstream bradykinin generation; several studies showed that lanadelumab potentiates the therapeutic preventive effect for angioedema development [29][30][31][32]. Berotralstat suppresses the development of angioedema by the inhibitory action of plasma kallikrein, subsequently decreases bradykinin production, and shows strong regulatory action for angioedema; this efficacy was confirmed by several clinical studies [33][34][35][36].…”

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

“…We, therefore, recommend evaluating patients with HAE for LTP at every visit, taking disease activity, burden, and control as well as patient preference into consideration (Recommendation 14). 182 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 As all of these factors can vary over time, all patients should be evaluated for LTP at least once a year. The goal of LTP is to achieve full control of disease burden while attempting to minimize treatment burden and side effects.…”

“… 195 , 235 , 236 , 237 It is typically administered as 300 mg every 2 weeks; however, a dosing interval of 300 mg every 4 weeks may be considered if a patient is well controlled (eg, attack free). 196 , 238 It appears safe with the rate of adverse events not appreciably higher among patients who received lanadelumab than among those who received placebo. 195 , 204 …”

“…For lanadelumab, and to some extent for C1–INH, adapting the dose and/or treatment interval, after achieving complete response, can decrease treatment burden. 196 , 219 , 220 Changes in the dose or the treatment intervals should be based on data obtained using patient-reported outcome measures. Poor control should prompt treatment optimization including consideration of switching LTP medication to improve efficacy.…”

The place of scales and questionnaires in assessing the disease’s severity and the long-term prophylaxis’s prescribing in patients with hereditary angioedema

“…Кроме того, AAS28, AECT, AE-QoL могут использоваться для оценки тяжести течения не только НАО, но и других видов АО без крапивницы [18]. Данные оценочные инструменты применяются не только в реальной клинической практике, но и во многих исследованиях современных препаратов для лечения НАО [18,19].…”